Pharming Group's total inventories for the quarter that ended in Mar. 2026 was €55.9 Mil. Pharming Group's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €55.6 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Pharming Group's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €0.03.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Pharming Group's Days Inventory for the
three
months ended in Mar. 2026 was 883.48.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Pharming Group's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.10.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharming Group's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.89.
Pharming Group (XAMS:PHARM) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Pharming Group's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharming Group's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Pharming Group Total Inventories Related Terms
Pharming Group Total Inventories Historical Data
* Premium members only.
The historical data trend for Pharming Group's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Pharming Group (XAMS:PHARM) has a Total Inventories of €55.9 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Pharming Group and its competitors.
Is Pharming Group's Total Inventories too high?
Pharming Group's current Total Inventories is €55.9 Mil. Overall, Pharming Group has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Total Inventories compare to VRTX and REGN?
Pharming Group's Total Inventories of €55.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Pharming Group and its competitors. Pharming Group's current Total Inventories is €55.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (XAMS:PHARM) is currently considered Fairly Valued. The stock's GF Value™ is €1.26, compared to a current price of €1.15 — trading 8.8% below its estimated fair value. The current Total Inventories is €55.9 Mil. Pharming Group's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Pharming Group (XAMS:PHARM), the current Total Inventories is €55.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (XAMS:PHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of €1.15 is trading 8.8% below its estimated GF Value™ of €1.26.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for XAMS:PHARM:
Total Inventories: €55.9 Mil
GF Value™: €1.26 vs. price of €1.15 (8.8% below fair value)
No single metric tells the full story. See the XAMS:PHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
80GF Score
Get the complete analysis for XAMS:PHARM
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XAMS:PHARM has been successfully added to your 
